en · de · es · fr · pt
retatrutide-notes.peptides3626.com › Topic › �¸‰重受体激动剂的分子设计 — 2026 Update

�¸‰重受体激动剂的分子设计 — 2026 Update

By Editorial Desk · published 2026-06-02 · last reviewed 2026-07-13 · Topic

Everything below concerns 肠促胰素. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-07-13. Where a claim depends on a specific study, the study is described rather than over-claimed.

三重受体激动剂的分子设计

化学修饰延长了分子在体内的停留时间,使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除,非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性,需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。

该化合物处于临床试验阶段,尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录,完整数据仍在逐步披露。关于长期疗效与安全性的判断,需要等待规模更大、随访更久的研究结果,目前不宜对最终结论作出预判。

retatrutide 是一种人工合成的多肽,设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子,而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础,经过非天然氨基酸替换和脂肪酸侧链修饰,以获得更长的作用时间。该方向属于多受体激动剂研究的一部分,与双重激动剂的工作并行推进。

Background and Receptor Pharmacology

Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.

Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.

The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.

Retatrutide at a glance

PropertyValueNotes
分子类别合成多肽含非天然氨基酸与脂肪酸侧链
分子量约 4.7 kDa多肽量级,精确值随计法而异
外观白色至类白色冻干粉常见冻干形态,供复溶使用
溶解性易溶于水复溶后为澄清至微乳光液体
常见同义词LY3437943开发阶段使用的代号

Handling, Storage, and Analytical Verification

Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.

Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.

Related pages on this site

Peptide Identity and Receptor Targets

Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.

Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.

Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.

Supporting material

=== Acute === According to the EPS, chlorothalonil is a toxicity category I eye irritant, producing severe eye irritation. It is in toxicity category II, "moderately toxic", if inhaled (inhaled LD50 0.094 mg/L in rats.) For skin contact and ingestion, chlorothalonil is rated toxicity category IV, "practically nontoxic", meaning the oral and dermal LD50 is greater than 10,000 mg/kg.

== Status at birth == As with many other European monarchs during World War II, King Peter II left his country to establish a government-in-exile. He left Yugoslavia in April 1941 and arrived in London in June 1941. The Royal Yugoslav Armed Forces capitulated in 18 April. After the Tehran Conference, the Allies shifted support from royalist Chetniks to communist-led Partisans. Commenting on the event and what happened to his father, Crown Prince Alexander said, "He [Peter II] was too straight. He could not believe that his allies – the mighty American democracy and his relatives and friends in London – could do him in. But that's precisely what happened". In June 1944, Ivan Šubašić, the Royalist prime minister, and Josip Broz Tito, the Communist Partisan leader, signed an agreement that was an attempt to merge the royal government and communist movement. On 29 November 1943, AVNOJ (formed by the Partisans) declared themselves the sovereign communist government of Yugoslavia and announced that they would take away all legal rights from the Royal government. On 10 August 1945, less than a month after Alexander's birth, AVNOJ named the country Democratic Federal Yugoslavia. On 29 November 1945, the country was declared a communist republic and changed its name to People's Federal Republic of Yugoslavia. In 1947, all members of Alexander's family except for his granduncle Prince George were deprived of their Yugoslav citizenship and their property was confiscated.

N-Acetylputrescine (NacPut), also known as monoacetylputrescine, is an endogenous metabolite of putrescine and a precursor and metabolic intermediate in the biosynthesis of γ-aminobutyric acid (GABA) from putrescine. The metabolic pathway is specifically putrescine into N-acetylputrescine by putrescine acetyltransferase (PAT), N-acetylputrescine into N-acetyl-γ-aminobutyraldehyde (N-acetyl-GABAL or N-acetyl-GABA aldehyde) by monoamine oxidase B (MAO-B), N-acetyl-GABAL into N-acetyl-γ-aminobutyric acid (N-acetyl-GABA) by aldehyde dehydrogenase (ALDH), and N-acetyl-GABA into GABA by an unknown deacetylase enzyme. This pathway is a minor alternative pathway to the major and primary pathway in which GABA is synthesized from glutamate. There is also another alternative pathway in which putrescine is converted into GABA with γ-aminobutyraldehyde (GABAL or GABA aldehyde) as an intermediate instead. It has been estimated that about 2 to 3% of GABA is synthesized from putrescine in the mouse brain, whereas in the case of the rat brain, the amount was negligible. In 2021, it was discovered that MAO-B does not mediate dopamine catabolism in the rodent striatum but instead participates in striatal GABA synthesis and that synthesized GABA in turn inhibits dopaminergic neurons in this brain area. It has been found that MAO-B, via the putrescine pathway, importantly mediates GABA synthesis in astrocytes in various brain areas, including in the hippocampus, cerebellum, striatum, cerebral cortex, and substantia nigra pars compacta (SNpc).

Sources: en.wikipedia.org

Supporting material

Polymer-protein hybrids are a class of nanostructure composed of protein-polymer conjugates (i.e. complexes composed of one protein attached to one or more polymer chains). The protein component generally gives the advantages of biocompatibility and biodegradability, as many proteins are produced naturally by the body and are therefore well tolerated and metabolized. Although proteins are used as targeted therapy drugs, the main limitations—the lack of stability and insufficient circulation times still remain. Therefore, protein-polymer conjugates have been investigated to further enhance pharmacologic behavior and stability. By adjusting the chemical structure of the protein-polymer conjugates, polymer-protein particles with unique structures and functions, such as stimulus responsiveness, enrichment in specific tissue types, and enzyme activity, can be synthesized. Polymer-protein particles have been the focus of much research recently because they possess potential uses including bioseparations, imaging, biosensing, gene and drug delivery.

== Recent research == Recent research has been directed towards finding better treatment options. Multi-drug therapy using insulin sensitizers, such as metformin and pioglitazone, has been linked to improving residual insulin action. High doses of insulin-like growth factor 1 has also been effective in patients with Rabson–Mendenhall syndrome. Though there is no cure, researchers remain optimistic on finding a cure.

Geranylgeraniol 18-hydroxylase is a cytochrome P450 protein containing heme, isolated from Croton sublyratus. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate.

In chemistry, yield, also known as reaction yield or chemical yield, refers to the amount of product obtained in a chemical reaction. Yield is one of the primary factors that scientists must consider in organic and inorganic chemical synthesis processes. In chemical reaction engineering, "yield", "conversion" and "selectivity" are terms used to describe ratios of how much of a reactant was consumed (conversion), how much desired product was formed (yield) in relation to the undesired product (selectivity), represented as X, Y, and S. The term yield also plays an important role in analytical chemistry, as individual compounds are recovered in purification processes in a range from quantitative yield (100 %) to low yield (< 50 %).

Sources: en.wikipedia.org

Notes from published material

The Min System is a mechanism composed of three proteins MinC, MinD, and MinE used by E. coli as a means of properly localizing the septum prior to cell division. Each component participates in generating a dynamic oscillation of FtsZ protein inhibition between the two bacterial poles to precisely specify the mid-zone of the cell, allowing the cell to accurately divide in two. This system is known to function in conjunction with a second negative regulatory system, the nucleoid occlusion system (NO), to ensure proper spatial and temporal regulation of chromosomal segregation and division.

Historically, men's pain has been treated as abnormal and requiring medical intervention, while women's pain, especially related to menstruation and childbirth, was considered normal and often left untreated. The perception of menstruation-related pain as natural—sometimes reinforced by religious narratives—contributed to this neglect. Pain relief in childbirth gradually advanced, with chemical anesthesia introduced in the 19th century, and techniques such as pain-free childbirth in 1950s France. Epidural anesthesia became common from the 1980s onward. Menstrual pain and conditions like endometriosis (affecting around 10% of women) have only been widely recognized by the medical profession since the late 2010s. Endometriosis was officially recognized as a medical condition in France in 1990. A national awareness plan was launched in 2019, and the disease was classified as a long-term illness in 2022. Some studies suggest that women may delay seeking care, often prioritizing family responsibilities and underestimating their symptoms.

==== Australia ==== On 10 March 2022, Brazil's Agriculture Ministry announced the country was holding talks with Australia about agricultural trade agreements regarding wheat, barley and pork trade as well as sustainable agriculture including research projects between both countries.

== CART receptor == The putative receptor target for CART evaded identification through 2011, however in vitro studies strongly suggested that CART binds to a specific G protein-coupled receptor coupled to Gi/Go, resulting in increased ERK release inside the cell. Results from a 2020 study suggested CART was a ligand for GPR160, but this finding was later challenged by the finding that GPR160 does not show specific binding to a radiolabeled version of CART either in a human cancer cell line that endogeneously expresses GPR160, or in a cell line that was transfected with GPR160. Furthermore, CART does not induce GPR160 mediated signaling in human cells. Several fragments of CART have been tested to try and uncover the pharmacophore, but the natural splicing products CART(55–102) and CART(62–102) are still of highest activity, with the reduced activity of smaller fragments thought to indicate that a compact structure retaining all three of CART's disulphide bonds is preferred.

On 20 September 2014, while speaking to party workers in Multan, Bhutto Zardari said, "I will take back Kashmir, all of it, and I will not leave behind a single inch of it because, like the other provinces, it belongs to Pakistan." The statement was to be the first marking his stance on the Kashmir issue and remarked upon widely in local and international media. On 6 February 2019, Bhutto Zardari met with the Kashmir Council in Washington to express solidarity with the people of Kashmir. During the meeting, he assured the delegation that he would continue to raise his voice against the brutalities of Indian forces against innocent and unarmed Kashmiri people at every available forum both nationally and internationally. He said that loyalty to the cause of Kashmir was in his blood and he would stand with the people of Indian-administered Kashmir in their just struggle for the right to self-determination and freedom from illegal and immoral Indian occupation. On 15 October 2022, after U.S. President Joe Biden referred to Pakistan as "one of the most dangerous nations in the world" and as a carrier of "nuclear weapons without any cohesion" at a Democratic Party fundraiser in California, Bhutto Zardari summoned American diplomat Donald Blome to the Ministry of Foreign Affairs and demanded an explanation as well as called for an official démarche.

Sources: en.wikipedia.org

Frequently asked questions

三重激动指的是什么?

指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。

为什么要做化学修饰?

天然肽类在体内容易被酶解并快速清除。脂肪酸侧链与非天然氨基酸可以延缓清除、降低酶解速率。修饰后的分子因此更适合较长间隔的给药安排。

目前证据处于什么阶段?

公开资料主要来自临床阶段的报告与注册平台记录。这些材料提供的是阶段性信息,而非最终结论。完整的安全性与有效性数据仍在积累中。

What class of drug is retatrutide?

It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.

Network